How often should rubitin/rubicatin (Zanbega) be administered and instructions for treatment schedule

Lurbinectedin (Lurbinectedin) is a targeted anti-tumor nucleic acid-binding inhibitor, mainly used to treat patients with recurrent small cell lung cancer (SCLC). The method of administration is intravenous infusion, and the drug directly acts on the DNA of tumor cells, thereby inhibiting the transcription and proliferation of cancer cells and inducing apoptosis. When using this drug, patients need to strictly abide by the infusion frequency and treatment schedule to ensure efficacy and safety.

The standard dosing regimen is an intravenous infusion every 3 weeks (21 days). The dose per infusion is calculated based on body surface area and is typically 3.2 mg/m². During the infusion process, medical staff will closely monitor the patient's vital signs and possible adverse reactions, such as bone marrow suppression, thrombocytopenia, anemia or gastrointestinal reactions, to facilitate timely intervention and treatment.

In terms of treatment schedule, patients usually need to complete at least several cycles of treatment before the efficacy can be evaluated. Maintain a 21-day interval between each cycle to ensure that the drug is fully metabolized in the patient's body and the hematological indicators are restored. If severe bone marrow suppression or other intolerable adverse reactions occur, the next cycle can be delayed or the dose can be adjusted appropriately under the guidance of a doctor.

During the entire course of treatment, patients need to undergo regular blood routine, liver and kidney function and imaging examinations to evaluate the efficacy and safety of the drug. At the same time, maintaining the infusion rate and monitoring time as directed by the doctor is critical to reducing infusion-related risks and optimizing efficacy. Through standardized dosing frequency and treatment schedule, rubicatin can maximize its anti-tumor effect while ensuring safety.

Reference materials:https://www.drugs.com/